source
- Relay Therapeutics reports promising Phase 2 results for zovegalisib; Eli Lilly leads R&D performance rankingRelay Therapeutics announced positive Phase 2 data for its experimental drug zovegalisib, which targets rare diseases that cause abnormal blood vessel development. The company said the results were…
- Eli Lilly Leads Both Innovation and Invention Rankings in Pharma R&D PerformanceSTAT+ reports that Eli Lilly captured the top positions in a prominent pharma R&D performance ranking, leading both the innovation and invention categories. The rankings, compiled by UK-based IDEA…